文献速递血管炎

免疫抑制治疗选择性影响血管炎疫苗接种患者对SARS-CoV-2的体液和细胞免疫应答

Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

该研究纳入56例接受两剂BNT162b2疫苗的GCA患者,最终44例可评估,以51名健康者为对照。91%的GCA患者产生S-IgG抗体应答但显著低于对照(100%),16%未检出中和活性,30%缺乏细胞应答;MTX显著抑制体液应答,糖皮质激素影响细胞应答,托珠单抗不影响任何免疫应答水平。

要点

  • GCA患者S-IgG应答率91%显著低于健康对照100%(P<0.0001),16%未检出中和活性。
  • MTX显著抑制S-IgG和NtAb体液应答,糖皮质激素影响细胞应答,托珠单抗不影响免疫应答。
  • 30%的GCA患者缺乏细胞免疫保护(对照0%,P<0.0001)。

核心结论

  • GCA患者虽看似获得稳健的抗体血清转化,但中和活性显著受损。
  • MTX显著降低体液应答的所有水平。
  • 多达三分之一的患者对COVID-19疫苗接种未产生细胞免疫保护。

研究设计与样本

  • 连续纳入接受两剂BNT162b2疫苗的GCA患者,在基线和第二剂后3周评估,健康受试者(n=51)为对照。
  • 纳入56例GCA患者,排除既往COVID-19证据和不完整随访后44例可评估。
  • 体液应答采用Spike特异性IgG抗体应答(S-IgG)和中和抗体(NtAb)评估,特异性T细胞应答采用酶联免疫斑点(ELISpot)评估。

主要发现

  • 91%的GCA患者显示抗体(S-IgG)应答,但显著低于健康对照(100%);P<0.0001。
  • 16%的GCA患者未检测到中和活性。
  • GCA患者抗体滴度(S-IgG和NtAb)显著低于健康对照。
  • 体液应答(S-IgG和NtAb)受MTX治疗显著抑制。
  • 30%的GCA患者缺乏细胞应答(健康对照为0%;P<0.0001),细胞应答显著受基线外周T淋巴细胞水平和糖皮质激素治疗影响。

关键数值与推荐

  • GCA患者S-IgG应答率91% vs 健康对照100%(P<0.0001)。
  • GCA患者细胞应答缺乏率30% vs 健康对照0%(P<0.0001)。
  • 16%的GCA患者未检测到中和活性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyse humoral and cellular immune response to mRNA COVID-19 vaccines in patients with GCA. METHODS: Consecutive patients with a diagnosis of GCA receiving two doses of BNT162b2 vaccine were assessed at baseline and 3 weeks from the second vaccine dose. Healthy subjects (n = 51) were included as controls (HC). Humoral response was assessed with Spike-specific IgG antibody response (S-IgG) and neutralizing antibodies (NtAb). Specific T cell response was assessed by enzyme linked immunosorbent spot (ELISpot). RESULTS: Of 56 included patients with GCA, 44 were eligible after exclusion of previous evidence of COVID-19 and incomplete follow-up. A significant proportion of patients with GCA (91%) demonstrated antibody (S-IgG) response, but this was significantly lower than HCs (100%); P < 0.0001. Neutralizing activity was not detected in 16% of patients with GCA. Antibody titres (S-IgG and NtAb) were significantly lower compared with HCs. Humoral response (S-IgG and NtAb) was significantly hampered by treatment with MTX. Cellular response was lacking in 30% of patients with GCA (vs 0% in HCs; P < 0.0001). Cellular response was significantly influenced by the levels of baseline peripheral T-lymphocytes and by glucocorticoid treatment. Treatment with tocilizumab did not affect any level of the immune response elicited by vaccination. CONCLUSIONS: Although patients with GCA apparently achieve a robust antibody seroconversion, there is a significant impairment of the neutralizing activity. MTX significantly reduced all levels of the humoral response. Up to one-third of patients do not develop a cellular immune protection in response to COVID-19 vaccination.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Monti S, Fornara C, Delvino P, et al. Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis. Rheumatology (Oxford). 2023. PMID: 35736379. doi:10.1093/rheumatology/keac365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。